Vaxcyte, Inc. (PCVX)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Vaxcyte, Inc. (PCVX) is up 12.9% since the beginning of the year. At $52 per share, PCVX is trading 19.8% below its 52-week high of $65. Investors who bought $1,000 worth of PCVX shares 5 years ago would now be looking at an investment worth $2,426.

Vaxcyte, Inc. (PCVX) has returned 12.94% so far this year and 58.53% over the past 12 months.

Based on dividend-adjusted daily data since Jun 12, 2020, PCVX's average daily return is +0.15%, while the average monthly return is +2.73%. At this rate, an investment would double in approximately 2.1 years.

Historically, 51% of months were positive and 49% were negative. The best month was Oct 2022 with a return of +81.7%, while the worst month was Mar 2025 at -48.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 7 months.

On a daily basis, PCVX closed higher 50% of trading days. The best single day was Oct 24, 2022 with a return of +60.4%, while the worst single day was Mar 31, 2025 at -45.6%.

Vaxcyte, Inc. has an annualized alpha of 25.86%, beta of 0.86, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since June 12, 2020.

• This stock captured 163.99% of S&P 500 Index gains and 158.24% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

PCVX ranks 75 for risk / return — better than 75% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Vaxcyte, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Vaxcyte, Inc. was 76.22%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current Vaxcyte, Inc. drawdown is 55.81%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Vaxcyte, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Vaxcyte, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.